Johnson & Johnson can be in preliminary talks with Merck, a main American pharmaceutical company, about utilizing its manufacturing traces, considered one of a number of concepts that federal well being officers mentioned with the Biden transition workforce. Federal officers are all for boosting the nation’s vaccine-making energy long-term, and Merck’s services could also be among the many few with remaining manufacturing functionality.
But Dr. McClellan, who sits on Johnson & Johnson’s board of administrators, mentioned it will take months to adapt Merck’s manufacturing facility to produce Johnson & Johnson’s vaccine. A senior administration official predicted that it might take till the tip of the year.
Other vaccine makers may come by means of by midyear. Novavax has labored to iron out what had been just lately dire manufacturing issues that delayed its scientific trials. Moncef Slaoui, the chief scientific adviser for the Trump administration’s vaccine growth program, mentioned in a current interview that Novavax might apply for emergency use authorization in late April. The authorities has already ordered 110 million doses of the Novavax vaccine, to be delivered by the tip of June, and Novavax has mentioned it believes it may possibly meet that focus on.
Mr. Biden has surrounded himself with new well being officers assigned to getting vaccines from factories to recipients, together with Dr. Bechara Choucair, the previous Chicago well being commissioner who’s the White House’s vaccinations coordinator, and Tim Manning, a former high official on the Federal Emergency Management Agency who’s now the provision coordinator. Dr. David A. Kessler, the previous F.D.A. commissioner, will assist lead the federal authorities’s vaccine growth program on the Department of Health and Human Services, with particular consideration to manufacturing.
After each the Pfizer-BioNTech and Moderna vaccines proved to be extremely efficient in scientific trials late final year, the Trump administration thought-about whether or not to rethink its technique of backing six completely different vaccine makers and as an alternative throw all of its weight behind the confirmed producers. One senior administration official described “countless hours of debate” over the difficulty.
In the tip, officers determined it was vital to preserve aiming for a broad portfolio of vaccines, partly as a result of nobody has discovered which vaccines would possibly work greatest for kids or be best towards rising variants. They really helpful that the Biden administration do the identical.
Katie Thomas and Donald G. McNeil Jr. contributed reporting.